Sun Pharmaceutical Industries Limited shareholders approved the reclassification of certain individuals from the Promoter Group to the Public shareholder category on September 26, 2026. This decision aligns with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The approval follows a series of intimations issued by the company on May 14, May 22, May 26, August 6, and August 25, 2026. The move formalizes the change in status for the persons referred to in the initial May 14 intimation.

Postal Ballot Process Completion

The Postal Ballot process was initiated pursuant to a Notice dated August 25, 2026. The remote e-voting period commenced on August 28, 2026, and concluded on September 26, 2026. The resolution set out in the Notice was duly approved by shareholders by the requisite majority.

Details of the voting results have been submitted to the stock exchanges. The Scrutinizer's Report is available on the Company's website at www.sunpharma.com .

Impact on Shareholding Patterns

The company stated that the effect of this reclassification will be reflected in subsequent quarterly shareholding patterns. These filings will be submitted to stock exchanges in accordance with applicable SEBI Listing Regulations provisions.

Procedural Compliance

The intimation was made in compliance with SEBI Listing Regulations requirements regarding changes in promoter group composition. The Company Secretary and Compliance Officer, Anoop Deshpande, signed the digital submission confirming the shareholder approval.

Sun Pharmaceutical Industries Limited announced an exclusive licensing agreement with LIB Therapeutics Inc. to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. The deal grants Sun Pharma access to a rapidly growing cardiovascular market valued at $3.7 billion outside the US and China.

Lerodalcibep, a once-monthly PCSK9 inhibitor for lowering LDL cholesterol, received EU approval under the brand name Lyrokaul on September 21, 2026. The drug is also approved in the US as Lerochol. Under the terms, LIB Therapeutics will receive upfront payments, future milestone payments, and royalties based on net sales in the licensed territories.

Market opportunity and strategic fit

The partnership strengthens Sun Pharma’s Innovative Medicines portfolio by entering the competitive lipid-lowering segment. According to IQVIA data cited in the release, the PCSK9 inhibitor market outside the US and China reached $3.7 billion in the period ending Q2 2026 (MAT Q2 2026). This represents a compound annual growth rate (CAGR) of 38% over the preceding two years. Europe alone accounted for $2.9 billion of this market size.

The global PCSK9 market is projected to approach $7 billion in 2026. This expansion is driven by updated guidelines emphasizing lower LDL-C targets for patients at high and very high cardiovascular risk.

Clinical profile and regulatory status

Lerodalcibep is a novel antibody-mimetic biologic administered via subcutaneous injection. Key features highlighted in the announcement include:

• Dosing: Once-monthly 300 mg/1.2 mL injection.
• Storage: Six-month ambient storage capability at room temperature (up to 25°C) after removal from refrigeration.
• Efficacy: Sustained reductions in low-density lipoprotein cholesterol (LDL-C).
• Safety: Most frequently reported adverse reactions include injection site reactions (6.7%), erythema (3.6%), and bruising (1.6%).

The drug is indicated for adults with primary hypercholesterolaemia or mixed dyslipidaemia who cannot reach LDL-C goals with statins alone or are statin intolerant.

What the numbers show

The agreement highlights a significant divergence between market growth and current treatment gaps. While the ex-US/China PCSK9 market grew at a robust 38% CAGR over the last two years, real-world data from the DA VINCI study indicates that only 33% of patients on stable oral lipid-lowering therapy achieved their LDL-C goals. This suggests substantial unmet need remains despite available therapies, positioning lerodalcibep’s convenience features (monthly dosing, ambient storage) as key differentiators for broader adoption in Sun Pharma’s licensed markets.